JPWO2020247603A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020247603A5 JPWO2020247603A5 JP2021572445A JP2021572445A JPWO2020247603A5 JP WO2020247603 A5 JPWO2020247603 A5 JP WO2020247603A5 JP 2021572445 A JP2021572445 A JP 2021572445A JP 2021572445 A JP2021572445 A JP 2021572445A JP WO2020247603 A5 JPWO2020247603 A5 JP WO2020247603A5
- Authority
- JP
- Japan
- Prior art keywords
- solid oral
- dosage form
- oral dosage
- weight
- amisulpride
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 claims 59
- 239000006186 oral dosage form Substances 0.000 claims 48
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 41
- 229960003036 amisulpride Drugs 0.000 claims 41
- 208000024714 major depressive disease Diseases 0.000 claims 31
- 238000013268 sustained release Methods 0.000 claims 25
- 239000012730 sustained-release form Substances 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 20
- 239000003814 drug Substances 0.000 claims 20
- 201000000980 schizophrenia Diseases 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 208000020016 psychiatric disease Diseases 0.000 claims 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 10
- 239000003795 chemical substances by application Substances 0.000 claims 10
- 208000024891 symptom Diseases 0.000 claims 10
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 9
- 239000000945 filler Substances 0.000 claims 9
- 239000012458 free base Substances 0.000 claims 8
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 8
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 8
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 8
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 8
- 239000011230 binding agent Substances 0.000 claims 7
- 238000004090 dissolution Methods 0.000 claims 7
- 238000007922 dissolution test Methods 0.000 claims 7
- 230000002496 gastric effect Effects 0.000 claims 7
- 239000008187 granular material Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 6
- 208000020401 Depressive disease Diseases 0.000 claims 5
- 229920003086 cellulose ether Polymers 0.000 claims 5
- 239000000314 lubricant Substances 0.000 claims 5
- 235000010355 mannitol Nutrition 0.000 claims 5
- 230000002085 persistent effect Effects 0.000 claims 5
- 239000002552 dosage form Substances 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 4
- 239000008203 oral pharmaceutical composition Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
- 238000009506 drug dissolution testing Methods 0.000 claims 2
- 235000019359 magnesium stearate Nutrition 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962856863P | 2019-06-04 | 2019-06-04 | |
| US62/856,863 | 2019-06-04 | ||
| US202063011584P | 2020-04-17 | 2020-04-17 | |
| US63/011,584 | 2020-04-17 | ||
| PCT/US2020/036084 WO2020247603A1 (en) | 2019-06-04 | 2020-06-04 | Modified release formulations and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535894A JP2022535894A (ja) | 2022-08-10 |
| JP2022535894A5 JP2022535894A5 (https=) | 2023-06-13 |
| JPWO2020247603A5 true JPWO2020247603A5 (https=) | 2023-06-13 |
Family
ID=73652146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572445A Pending JP2022535894A (ja) | 2019-06-04 | 2020-06-04 | 放出調節製剤およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220323409A1 (https=) |
| EP (1) | EP3980008A4 (https=) |
| JP (1) | JP2022535894A (https=) |
| WO (1) | WO2020247603A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018378348B2 (en) | 2017-12-05 | 2024-09-19 | Sunovion Pharmaceuticals Inc. | Crystal forms and production methods thereof |
| CA3084953A1 (en) | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| AU2020286441A1 (en) | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
| CN115487161B (zh) * | 2022-11-18 | 2023-03-03 | 山东则正医药技术有限公司 | 一种氨磺必利片的制备方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2762213B1 (fr) * | 1997-04-18 | 1999-05-14 | Synthelabo | Composition pharmaceutique a retention gastrique |
| WO2010023690A2 (en) * | 2008-08-28 | 2010-03-04 | Torrent Pharmaceuticals Ltd. | Prolonged release formulation of amisulpride |
| GB201004020D0 (en) * | 2010-03-11 | 2010-04-21 | Acacia Pharma Ltd | New therapeutic use |
| US10441544B2 (en) * | 2017-10-10 | 2019-10-15 | Douglas Pharmaceuticals, Ltd. | Extended release pharmaceutical formulation |
| CA3084953A1 (en) * | 2017-12-05 | 2019-06-13 | Sunovion Pharmaceuticals Inc. | Nonracemic mixtures and uses thereof |
| AU2020286441A1 (en) * | 2019-06-04 | 2022-01-06 | Sunovion Pharmaceuticals Inc. | Modified release formulations and uses thereof |
-
2020
- 2020-06-04 WO PCT/US2020/036084 patent/WO2020247603A1/en not_active Ceased
- 2020-06-04 EP EP20819312.8A patent/EP3980008A4/en not_active Withdrawn
- 2020-06-04 US US17/616,460 patent/US20220323409A1/en not_active Abandoned
- 2020-06-04 JP JP2021572445A patent/JP2022535894A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7374781B2 (en) | Sustained release formulations containing acetaminophen and tramadol | |
| WO2009034541A9 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
| RU2006122517A (ru) | Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779 | |
| AU2012349771A1 (en) | Methods for treating cardiovascular disorder | |
| RU2008137229A (ru) | Ниацинсодержащая фармацевтическая композиция (варианты) и таблеточный препарат (варианты), способ снижения гиперемии и способ приготовления ниацинсодержащей таблетки | |
| EP3013327B1 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
| KR20100008356A (ko) | 칼슘채널길항제를 포함하는 약제학적 제제 | |
| WO2021129735A1 (zh) | 一种固体制剂及其制备方法和用途 | |
| AU2011288256A1 (en) | Oral controlled release pharmaceutical compositions of Blonanserin | |
| WO2023241688A1 (zh) | 一种用于治疗抗凝血的药物组合物及应用 | |
| CN101836967A (zh) | 二氢青蒿素的双层片及其制备方法 | |
| CN101766582A (zh) | 一种苯磺酸左旋氨氯地平的片剂及其制备方法 | |
| JPWO2020247603A5 (https=) | ||
| KR101128891B1 (ko) | 로라타딘 및 슈도에페드린을 함유하는 제어 방출 다층정 | |
| CN101342177B (zh) | 氯诺昔康双层缓释片 | |
| JPWO2020247627A5 (https=) | ||
| WO2006088864A1 (en) | Controlled release compositions comprising levetiracetam | |
| CN101002755A (zh) | 一种组合脉冲释放制剂及其制备方法 | |
| EP3727365A2 (en) | Modified release formulations of flurbiprofen | |
| KR20140118412A (ko) | 활성 성분으로 에페리손을 함유하는 서방성 제제 조성물 | |
| WO2007010501A2 (en) | A pharmaceutical composition comprising a combination of beta blocker and an ace inhibitor | |
| RU2798106C1 (ru) | Фармацевтическая композиция, содержащая этилметилгидроксипиридина сукцинат | |
| CN103040798A (zh) | 一种苯扎贝特缓释药物组合物 | |
| US20260069569A1 (en) | Ebselen containing oral dosage forms | |
| KR20200077911A (ko) | 잘토프로펜 함유 서방성 의약 조성물 |